Skip Navigation LinksHome > November/December 2010 - Volume 34 - Issue 6 > Proton Magnetic Resonance Spectroscopy in Differentiating Gl...
Journal of Computer Assisted Tomography:
doi: 10.1097/RCT.0b013e3181ec554e

Proton Magnetic Resonance Spectroscopy in Differentiating Glioblastomas From Primary Cerebral Lymphomas and Brain Metastases

Chawla, Sanjeev PhD; Zhang, Yu MS; Wang, Sumei MD; Chaudhary, Sangeeta MD; Chou, Chou BS; O'Rourke, Donald M. MD; Vossough, Arastoo PhD, MD; Melhem, Elias R. MD, PhD; Poptani, Harish PhD

Collapse Box


Objective: To differentiate glioblastomas, primary cerebral lymphomas (PCLs), and brain metastases using multivoxel proton magnetic resonance (MR) spectroscopic imaging.

Methods: A total of 56 patients with brain neoplasms underwent MR imaging and proton MR spectroscopic imaging. The data were analyzed from contrast-enhancing and peritumoral regions (PTR). N-acetylaspartate/creatine (Cr), choline (Cho)/Cr, glutamate+glutamine/Cr, myo-inositol/Cr, and lipids+lactate/Cr ratios were computed, and pairwise comparisons between neoplasms were made using Mann-Whitney U tests.

Results: The PTR demonstrated most significant differences in metabolite ratios. The Cho/Cr ratio in glioblastomas (0.46 [0.01]) was significantly higher than that in metastases (0.38 [0.02], P = 0.01). Significantly elevated Cho/Cr levels were also noted in PCLs (0.48 [0.03]) compared with those in metastases (P = 0.04). In addition, PCLs also demonstrated significantly higher lipids+lactate/Cr levels (11.83 [2.59]) compared with glioblastomas (4.50 [0.59], P = 0.003) and metastases (2.79 [0.33], P = 0.001).

Conclusions: Proton MR spectroscopic imaging from PTR may assist in the differentiation of glioblastomas, metastases, and PCLs.

Copyright © 2010 Wolters Kluwer Health, Inc. All rights reserved.



Article Tools


Article Level Metrics

Search for Similar Articles
You may search for similar articles that contain these same keywords or you may modify the keyword list to augment your search.